ALNY

Alnylam Pharmaceuticals Inc.

Price

$221.48

return (12m)

-51.96%

p/e

43.17

p/bv

25.76

DIVIDEND YIELD

0.00%

ALNY price

Alnylam Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ALNY

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-16.66%

3 months

-29.19%

1 year

-51.96%

2 years

-17.83%

5 years

13.57%

10 years

215.04%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals ALNY

Valuation

P/E

43.17

Sector -3.50

Industry -3.50

P/BV

25.76

Sector 1.98

Industry 1.98

P/Revenue (PSR)

7.26

Sector 2.03

Industry 2.03

EV/EBITDA

140.95

Sector -216.72

Industry -216.72

EV/EBIT

149.97

Sector -46.47

Industry -46.47

P/EBITDA

53.97

Sector -21.39

Industry -21.39

P/EBIT

58.97

Sector -27.84

Industry -27.84

P/Total Assets

6.27

Sector 1.16

Industry 1.16

P/Net Current Assets

83.94

Sector -10.64

Industry -10.64

P/Working Capital

11.22

Sector -139.65

Industry -139.65

EPS

5.84

Sector -1.78

Industry -1.78

BVPS

9.79

Sector 1.99

Industry 1.99

Efficiency

Gross Margin

79.72%

Sector 41.35%

Industry 41.35%

EBITDA Margin

17.91%

Sector -17,192.92%

Industry -17,192.92%

EBIT Margin

16.83%

Sector -4,203,320.32%

Industry -4,203,320.32%

Operating Margin

20.81%

Sector -35.47%

Industry -35.47%

Net Profit Margins

16.82%

Sector -35.90%

Industry -35.90%

Asset Turnover

0.23

Sector 0.03

Industry 0.03

Profitability

ROE

59.67%

Sector -57.40%

Industry -57.40%

ROA

14.54%

Sector -59.44%

Industry -59.44%

ROIC

Sector -2,370.21%

Industry -2,370.21%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

3.05

Sector 2.91

Industry 2.91

Net Debt / EBITDA

-9.94

Sector -21.98

Industry -21.98

Net Debt / EBIT

-10.57

Sector -8.44

Industry -8.44

Net Debt / Equity

-1.70

Sector -33,112.99

Industry -33,112.99

Gross Debt / Equity

0.75

Sector -0.85

Industry -0.85

Equity/Assets

0.24

Sector 0.46

Industry 0.46

Liabilities/Assets

0.76

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

41.59%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

Fundamentals ALNY

DRAG THE FRAME TO SEE MORE DATA

FAIR VALUE OF Alnylam Pharmaceuticals ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$221.48

Fair Value

$35.87

Upside

-83.81%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
ALNY Alnylam Pharmaceuticals Inc.	$221.48	-51.92%	0.00%	43.17	25.76	59.67%	16.82%
PFE Pfizer Inc.	$27.48	8.11%	6.08%	37.23	1.89	5.07%	6.80%
ABBV AbbVie Inc.	$259.97	9.77%	2.60%	73.78	-78.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$37.23	-33.47%	4.80%	9.44	5.02	53.11%	35.32%
MRK Merck & Co. Inc.	$143.18	65.09%	2.29%	114.37	8.64	7.56%	4.77%
AZN AstraZeneca PLC	$156.59	-4.79%	1.95%	19.85	5.12	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$60.33	34.57%	4.09%	13.50	5.62	41.59%	18.87%
ZTS Zoetis Inc.	$69.46	-51.82%	2.99%	11.07	9.27	83.77%	27.69%
AMGN Amgen Inc.	$402.15	38.44%	2.43%	25.29	18.92	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$729.88	22.13%	0.47%	18.75	2.56	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$108.98	45.42%	0.00%	32.57	93.84	288.13%	24.86%
MCK McKesson Corporation	$888.29	16.56%	0.38%	19.57	-26.84	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$501.27	24.01%	0.00%	30.03	6.53	21.76%	35.00%
CAH Cardinal Health Inc.	$226.17	45.05%	0.93%	30.18	-18.99	-62.92%	0.67%
ARGX argenx SE	$914.13	19.13%	0.00%	24.66	6.43	26.07%	25.78%
HRMY Harmony Biosciences Holdings Inc.	$39.41	46.40%	0.00%	13.11	2.38	18.14%	18.88%
BIIB Biogen Inc.	$220.34	42.87%	0.00%	39.95	1.77	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

ALNY - Historical Dividends

no dividend paid in the period.

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

ABOUT Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (7 people)

United States

24 years

Founded: 2002

2004

Time since IPO - 22 years

2.500

Employees

Alnylam Pharmaceuticals Inc. (United States) is listed on the Nasdaq and has a market capitalization of $34.88 billion, with shareholders equity totaling $1.35 billion.

The company employs approximately 2.500 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Alnylam Pharmaceuticals Inc. reported $4.80 billion in revenue, generating net income of $807.99 million.

Key financial metrics include a P/E ratio of 43.17, a price-to-book (P/B) ratio of 25.76, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ALNY.

Market cap

$34.88 billion

Net worth

$1.35 billion

$1,354,118,000.00

Assets

$5.56 billion

$5,558,769,000.00

Total Shares Outstanding

138.25 million

138,249,000

Average Daily Trading Volume

$1.15 million

$1,150,870.00

Sector

Health Care

Industry

Biotechnology

ALNY

revenue by Business Segment Alnylam Pharmaceuticals

Revenue by Region Alnylam Pharmaceuticals

ALNY revenue and profits

Financial Results ALNY

DRAG THE FRAME TO SEE MORE DATA

ALNY cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$888.29 20,83% (12M)

P/E

19.57

0.38%

ROE

-137.16%

P/BV

-26.84

CAH - Cardinal Health

$226.17 48,30% (12M)

P/E

30.18

0.93%

ROE

-62.92%

P/BV

-18.99

ABBV - AbbVie

$259.97 14,69% (12M)

P/E

73.78

2.60%

ROE

-106.44%

P/BV

-78.53

MRK - Merck & Co.

$143.18 66,83% (12M)

P/E

114.37

2.29%

ROE

7.56%

P/BV

8.64

AZN - AstraZeneca

$156.59 --6,84% (12M)

P/E

19.85

1.95%

ROE

25.77%

P/BV

5.12

PFE - Pfizer

$27.48 7,47% (12M)

P/E

37.23

6.08%

ROE

5.07%

P/BV

1.89

BMY - Bristol-Myers Squibb

$60.33 40,43% (12M)

P/E

13.50

4.09%

ROE

41.59%

P/BV

5.62

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$888.29 20,83% (12 M)

P/L

19.57

0.38%

ROE

-137.16%

P/VP

-26.84

CAH - Cardinal Health

$226.17 48,30% (12 M)

P/L

30.18

0.93%

ROE

-62.92%

P/VP

-18.99

ABBV - AbbVie

$259.97 14,69% (12 M)

P/L

73.78

2.60%

ROE

-106.44%

P/VP

-78.53

MRK - Merck & Co.

$143.18 66,83% (12 M)

P/L

114.37

2.29%

ROE

7.56%

P/VP

8.64

AZN - AstraZeneca

$156.59 --6,84% (12 M)

P/L

19.85

1.95%

ROE

25.77%

P/VP

5.12

PFE - Pfizer

$27.48 7,47% (12 M)

P/L

37.23

6.08%

ROE

5.07%

P/VP

1.89

BMY - Bristol-Myers Squibb

$60.33 40,43% (12 M)

P/L

13.50

4.09%

ROE

41.59%

P/VP

5.62

Frequently Asked Questions

What is the price of Alnylam Pharmaceuticals (ALNY) today?

The current price of Alnylam Pharmaceuticals (ALNY) is $221.48. The stock began the year trading around $397.65 and is currently priced at $221.48. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Alnylam Pharmaceuticals (ALNY) pay dividends?

Alnylam Pharmaceuticals (ALNY) did not pay dividends over the past year.

Is Alnylam Pharmaceuticals (ALNY) a good investment?

Alnylam Pharmaceuticals (ALNY) is currently trading at $221.48 with a P/E ratio of 43.17. This represents a -5,831% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was -51.96%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Alnylam Pharmaceuticals (ALNY) stock?

You can buy Alnylam Pharmaceuticals (ALNY) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol ALNY and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Alnylam Pharmaceuticals (ALNY) yield today?

Over the past month, Alnylam Pharmaceuticals (ALNY) has returned -16.66% — -51.96% over the past year, and 13.57% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Alnylam Pharmaceuticals (ALNY) today at the current price of $221.48 your total investment would be $22,147.50.

Based on historical performance, the investment would have grown to approximately:

$10,639.66 after 1 year
$25,152.92 after 5 years
$69,773.48 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

ALNY

Alnylam Pharmaceuticals Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment ALNY

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING ALNY WITH OTHER STOCK

ABOUT Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Inc.

United States

24 years

2004

2.500

PROFIT X PRICE ALNY

Financial Results ALNY

ALNY cash flow

Asset, Revenue and Profit Growth - ALNY

ALNY balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BMY - Bristol-Myers Squibb

Frequently Asked Questions